Cite
HARVARD Citation
Feldman, D. et al. (2020). Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 126 (24), pp. 5247-5255. [Online].